Management of patients with non-Hodgkin's lymphoma.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002051:Burkitt Lymphoma / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D006801:Humans; D008220:Lymphography; D008223:Lymphoma / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D008466:Mechlorethamine / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003520:Cyclophosphamide; D011241:Prednisone